Wegovy and asthma: what the clinical evidence actually shows

What the obesity-asthma research tells us, and why weight loss matters here

The link between excess weight and asthma is well-documented in the clinical literature. Adipose tissue promotes systemic inflammation, mechanically restricts the chest wall, and worsens airway hyperresponsiveness. Studies consistently show that people with obesity report more days with asthma symptoms, use reliever inhalers more often, and are admitted to hospital more frequently than people with asthma at a healthy weight. This is the backdrop against which any weight-loss intervention (including semaglutide) should be evaluated.

Semaglutide itself has anti-inflammatory properties beyond its weight-loss effect, acting on GLP-1 receptors in ways that reduce systemic inflammatory markers. The STEP 1 trial, published in the New England Journal of Medicine, demonstrated an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That degree of weight loss is associated in the broader obesity literature with meaningful improvements in peak expiratory flow, FEV1, and asthma symptom scores. Asthma was not a primary outcome of STEP 1, but participants with respiratory comorbidities were not excluded, and no adverse respiratory signal emerged from the trial data.

It is worth being clear about what the evidence does not yet show: there is no large, prospective, randomised trial specifically designed to measure semaglutide's effect on asthma outcomes. What exists is mechanistic plausibility, observational data linking weight loss to improved control, and the absence of respiratory safety signals in the semaglutide programme. That distinction matters for setting expectations, and it is one a prescriber should walk through with you.

Does Wegovy interact with asthma medicines?

Most asthma treatment is inhaled (salbutamol, beclometasone, fluticasone, formoterol) and inhaled medicines bypass the gastrointestinal tract entirely. Semaglutide's gastric-emptying effect does not apply to them. If your asthma is managed with an inhaler alone, there is no pharmacokinetic interaction to worry about.

Oral corticosteroids are a different consideration. Prednisolone courses and maintenance oral steroids are absorbed through the gut, and because semaglutide slows gastric motility, the rate of absorption of any oral medicine taken around the same time may change. This does not mean oral steroids become ineffective, but it is precisely the kind of detail a prescriber needs to know before writing a prescription. The NHS semaglutide medicines page lists this interaction class and advises patients to tell their prescriber about all current medicines, that includes reliever inhalers, preventer inhalers, and any oral or nebulised treatment.

There is a separate page on how semaglutide interacts with specific asthma medications if you want to go into that in more detail. The short version: inhaled therapy is generally unaffected; oral medicines warrant a conversation with your prescriber.

Eligibility when you have asthma, what a prescriber looks at

Asthma alone does not disqualify you from Wegovy. The licensed eligibility criteria for semaglutide in the UK cover adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. Asthma is not listed as a contraindication in the Wegovy SmPC, and poorly controlled asthma linked to obesity may even strengthen the clinical case for treatment.

What a prescriber does assess is the totality of your health picture: how well your asthma is controlled, which medicines you take, whether you have had any recent oral steroid courses, and whether any other factors (such as heart or liver conditions) need to be considered alongside. You can read about the cardiovascular evidence separately on the Wegovy and heart health page, and for liver-related questions the Wegovy and liver page covers the latest position.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, a real clinician, not an automated system, reviews your answers and medication history the same day. If you store your Wegovy pen in the fridge door next to everyday items, that is a normal part of life on this treatment; the prescriber's job is to make sure that pen is the right one for you in the first place. Details of how that process works are on the about us page.

Practical considerations if you have asthma and start Wegovy

The most common side effects of semaglutide are gastrointestinal: nausea, loose stools, reflux, and reduced appetite are most noticeable in the first few weeks or after a dose step. These are not asthma-specific, but if you already experience reflux (which is more common in people with obesity and can worsen airway irritation) it is worth flagging at consultation. Your prescriber can advise on timing and symptom management.

Breathing difficulties are not a recognised side effect of semaglutide. If you experience any new or worsening respiratory symptoms after starting treatment, you should contact your GP or asthma nurse promptly, as with any change in your condition. The broader semaglutide and asthma page covers the respiratory evidence in more depth.

Pregnancy is a separate consideration: Wegovy is not recommended during pregnancy, breastfeeding, or when trying to conceive, and that guidance applies regardless of any other conditions you have. There is more on that at Wegovy and pregnancy. If weight management is something you want to explore now, a good starting point is the treatment overview, which sets out what is available and how the process works. For context on what private treatment typically costs, the Wegovy prices page gives an honest picture. When you are ready to speak to a prescriber, you can start your free consultation at any point.